Description

Nicoumalone Tablet

Nicoumalone Tablets (1 mg / 2 mg / 3 mg / 4 mg)

Acenocoumarol BP / IP / USP — Oral Anticoagulant Therapy

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale exporter of advanced cardiovascular, hematology, and internal medicine therapeutics. We manufacture a comprehensive, internationally standardized range of Nicoumalone Tablets (1 mg / 2 mg / 3 mg / 4 mg) within our WHO–GMP certified, high-precision solid dosage manufacturing installations. This essential “Coumarin-Derivative Anticoagulant” acts as a major strategic product for cardiology networks, public hospital infrastructures, national health ministry tenders, and international B2B wholesale marketplaces across Europe, the CIS region, Africa, LATAM, and Southeast Asia.

Product Overview

This formulation operates as a “Vitamin K Reductase Inhibitor.” It ensures patient safety and prevents the propagation of dangerous intravascular blood clots by selectively down-regulating the liver’s synthesis of active clotting factors.

• Mechanism 1 (Epoxide Reductase Inhibition): Nicoumalone physically penetrates hepatic tissue and chemically blocks the enzyme Vitamin K Epoxide Reductase. This enzyme is responsible for converting inactive, oxidized vitamin K epoxide back into its active, reduced form ($KH_{2}$).

• Mechanism 2 (Coagulation Cascade Suppression): Depletion of active Vitamin K chemically prevents the gamma-carboxylation of glutamic acid residues on critical clotting proteins. This completely halts the physical production of functional Factors II (Prothrombin), VII, IX, and X, as well as anticoagulant Proteins C and S.

• Mechanism 3 (Optimized Kinetic Profile): Compared to older coumarins like Warfarin, Nicoumalone exhibits a shorter plasma half-life (approx. 8 to 11 hours). This allows for faster initial anticoagulation and rapid systemic clearance if the dose needs to be physically reversed due to surgery or bleeding complications.

Product Composition & Calibration Spectrum

We manufacture Nicoumalone in a complete, highly precise range of strengths to allow for the exact dosage adjustments required to maintain narrow therapeutic targets.

Technical & Logistics Specifications

• HS Code: 3004.90.99 (Medicaments acting on the blood and blood-forming organs / Anticoagulants)

• CAS Number: 152-72-7 (Nicoumalone / Acenocoumarol)

• Dosage Form: Oral Solid Tablet (Scored for safe, flexible division when split-dosing is required)

• Packaging Configurations: 10 or 14 Tablets per Blister packed exclusively in high-barrier Alu-Alu (Cold-Form Foil) or thick moisture-shield PVC/PVDC strips. Our premium tropicalized packaging physically blocks environmental humidity, guaranteeing a full 36-month shelf life in Zone IVb climates.

Manufacturing Authority & Compliance

• Micro-Dose Content Uniformity: Because Nicoumalone is highly potent and compressed at exceptionally low doses (1mg to 4mg) relative to total tablet mass, we employ Automated Multi-Stage Geometric Solid Blenders. This physically guarantees absolute chemical content uniformity across every tablet to prevent toxic dosing spikes.

• Aseptic Cross-Contamination Barriers: Due to the severe hemorrhagic risks associated with anticoagulant cross-contamination, our tableting processing lines run within HVAC-Isolated Negative-Pressure Suites, completely satisfying international B2B regulatory audits.

• Validated Release Profiles: Every production batch physically undergoes Comparative In-Vitro Dissolution Profiling, chemically ensuring that the tablet disintegrates and releases the API uniformly inside the gastrointestinal tract to establish predictable absorption curves.

Primary Indications

• Cardiology & Electrophysiology: Prevention of systemic thromboembolism in patients presenting with Atrial Fibrillation (AF) or undergoing mechanical/bioprosthetic Heart Valve Replacement.

• Hematology & Vascular Surgery: Treatment and long-term prophylaxis of Deep Vein Thrombosis (DVT) and acute Pulmonary Embolism (PE).

• Neurology Support: Secondary prevention of transient ischemic attacks (TIA) and ischemic stroke.

Usage Instructions

• The INR Mandate: Dosing must be chemically managed and titrated strictly based on regular International Normalized Ratio (INR) Blood Tests. The standard therapeutic target window is typically an INR of 2.0 to 3.0.

• Administration Consistency: The daily dose must be taken physically at the exact same time every day, preferably in the evening, on an empty stomach (1 hour before or 2 hours after a meal).

• Dietary Stabilization: Patients must maintain a highly stable dietary intake of Vitamin K rich foods (such as green leafy vegetables, spinach, kale). Sudden dietary changes can chemically interact with the mechanism of action, causing dangerous fluctuations in INR stability.

• The Bleeding Rule: Patients must be physically monitored for signs of excessive anticoagulation, including unexpected bruising, nosebleeds, dark tarry stools, or prolonged bleeding from minor cuts.

Safety Warning: HIGH-ALERT CRITICAL ANTICOAGULANT. For Specialist Supervision and Strict Laboratory Monitoring Only. Hemorrhage Risk: May cause severe, life-threatening internal or external bleeding; perform absolute compliance tracking. Interaction Management: Nicoumalone chemically interacts with numerous agents; drugs like NSAIDs (Ibuprofen, Aspirin) and specific broad-spectrum antibiotics physically increase bleeding risks significantly. Contraindication: Do not use in patients presenting with active clinical bleeding, severe hepatic or renal impairment, severe uncontrolled hypertension, or during pregnancy (high teratogenic fetal risk).

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export pipelines for the entire Nicoumalone dosage spectrum. Whether you are executing a procurement contract for a National Health Authority Tender across Europe or the CIS, stocking a cardiology cooperative hospital network in Africa, or maintaining an active inventory listing on an international digital B2B Pharmaceutical Marketplace across Southeast Asia or LATAM, we deliver all required documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for rapid entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in